How Do Imeglimin and Metformin Differ in Insulin and Incretin Effects?
An exploratory open-label RCT found imeglimin and metformin lowered HbA1c similarly, but only imeglimin raised insulin and GIP secretion. PICO summary and expert commentary.
Hormone Insight Editorial Team
Clinical archive
Do Gestational Diabetes Lipid Levels Predict Child Insulin Function at Age 9?
A secondary analysis of a metformin-versus-insulin gestational diabetes trial found cord serum lipids associated with offspring beta-cell function at age nine. PICO summary and expert commentary.
Does Weight Loss Affect Vitamin D Levels Differently in Women and Men?
A secondary analysis of a weight-loss-maintenance RCT found that low-calorie-diet weight loss raised serum 25(OH)D in both sexes, but further loss and low baseline vitamin D tracked with maintenance only in women. PICO summary and expert commentary.
Does Evolocumab Improve Heart Health in Type 1 Diabetes?
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.
Can Weekly Semaglutide Replace Mealtime Insulin in Type 2 Diabetes?
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
Is Automated Insulin Delivery Safe and Effective for Young Children?
In children aged 2-6 years with type 1 diabetes, the MiniMed 780G in auto mode improved time in range and HbA1c over manual mode with suspend-before-low, meeting non-inferiority with superiority. PICO summary and expert commentary.
Semaglutide and Walking Distance in PAD with Type 2 Diabetes: A STRIDE Subgroup Analysis
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
Does Tirzepatide Weight Loss Improve Quality of Life?
A secondary patient-reported-outcomes analysis of the SURMOUNT-1 phase 3 trial finds tirzepatide improved health-related quality of life versus placebo in adults with obesity, with larger gains at greater weight loss. PICO summary and expert commentary.
Tirzepatide vs Semaglutide for Obesity in Type 2 Diabetes: An Indirect Comparison
An industry-sponsored indirect treatment comparison suggesting tirzepatide 10 and 15 mg achieve greater weight, BMI and HbA1c reduction than semaglutide 2.4 mg in type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
ECC5004/AZD5004: First-in-Human Phase 1 Findings
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.